London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, BioAgilytix, regarding the acquisitions of 360biolabs® and MicroConstants.
BioAgilytix Labs, LLC (‘BioAgilytix’), a leading global Contract Research Laboratory, recently announced that it has acquired 360biolabs®, the most comprehensive Contract Research Organization in Australia and MicroConstants, the US-based industry leading bioanalytical service provider.
Located in Australia’s biomedical and clinical research hub, 360biolabs offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC-MS/MS small molecule capabilities. The transaction will expand BioAgilytix’s global footprint into jurisdictions of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adding further capacity by joining 360biolabs’ internationally recognised Quality systems (ISO/IEC 17025, ISO 15189, GLP and GCLP). “This planned acquisition is part of our strategic growth strategy to expand our capacity, expertise and agility to serve customers across all geographies, and we look forward to welcoming the 360biolabs team and integrating the business. Joining forces makes sense for our two organizations, but most importantly for our combined clients and the patients they serve.” said Jim Datin, Preseident and CEO of BioAgilytix.
MicroConstants, to be known as BioAgilytix San Diego, provides industry-leading services in method development, validation, and sample analysis for small and large molecule therapeutics and biomarkers. The business has deep expertise in bioanalytical testing services with over 20 years of experience and will complement BioAgilytix’s already impressive contract research services for the pharmaceutical and biotech industry. MicroConstants China remains a separate business entity and does not form part of this transaction. “We are excited to welcome the MicroConstants team to BioAgilytix and to work with them to integrate the business. We believe that by joining forces, BioAgilytix and MicroConstants will not only create significant scientific and performance synergies, but also we are better able to serve the growing biotechnology community on the West Coast.” said Jim Datin.
The 360biolabs acquisition is subject to Australian Foreign Investment Review Board (“FIRB”) requirements and receipt of FIRB approval. The acquisition is expected to close in the Q3.